S. Dai

发表

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies

K. Kwei, J. Burger, A. Tedeschi, 2022, Leukemia & lymphoma.

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

J. Byrd, U. Jaeger, T. Kipps, 2019, American journal of hematology.

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

R. Greil, J. Gribben, I. Flinn, 2022, Haematologica.

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.

J. Byrd, U. Jaeger, T. Kipps, 2019, Blood.

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

T. Kipps, J. Burger, A. Tedeschi, 2019, Leukemia.

Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.

J. Burger, A. Tedeschi, T. Robak, 2021 .

Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.

Jeffrey A Jones, J. Byrd, T. Kipps, 2017 .

Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

J. Byrd, S. Mulligan, S. O'brien, 2019, Leukemia & lymphoma.